Capable

Capable, a biotech startup backed by prominent investors, is using AI to develop peptide and nucleotide therapeutics that enhance human capabilities, starting with sleep. The company aims to create drugs that restore cognitive performance under sleep deprivation and eventually reduce sleep needs by 1-2 hours, targeting rare sleep disorders first.

HumansareCapableofGreatness Capable compiles frontier intelligence into frontier medicines. Backed by Our Team Rose Freeman Church Bird Du Pellier Pentelute Goldstein Dinsmore Allen Turaga de Lecea Hasan Further backed by Context In the age of ever-improving AI capabilities, we humans are lagging behind. We believe that humans are capable of more. Nature gave us clues on making this dream real. Research has given us insight into thousands of powerful rare variants . Program 1/4 We spend a third of our lives asleep. Yet, a small subset of humans thrive on four to six hours of sleep per night. They carry short sleeper variants, allowing them to remain healthy while being awake for longer. Previous research reports those short sleepers to have more energy, vigor, and disease resistance. While not definitive evidence, we see them as a proof-of-concept for our biggest frontier for improving human health. Our first four programs are in sleep. Concretely, we are first working on therapeutics that restore cognitive performance under sleep deprivation, and then towards the end-goal of allowing patients to sleep 1-2 hours less. Our initial focus will be on rare, undertreated sleep diseases like narcolepsy, hypersomnia, while gradually expanding a broader population such as via shift-work sleep disorders. The world's most successful drug is a peptide: In 2025, Tirzepatide made $36B. What's the model that will design the next Tirzepatide? We’re building a vertically integrated , AI-enabled , deeptech platform to rapidly explore and unlock new human capabilities.Frontier models won’t be bottlenecked by intelligence. They’ll be bottlenecked by the speed of data and active learning. Making peptide and nucleotide therapeutics rapidly with automated polymer synthesis.